A | Sanjay Dutt is back in the headlines, and this time it is for a project that seems to be stirring a lot of curiosity. After winning hearts with his performance as SP Chaudhary Aslam in Aditya Dhar’s Dhurandhar: The Revenge, where fans loved his comical answers and savage attitude, he has officially announced his next big project. Titled Aakhri Sawal, the film will release in cinemas on May 15, 2026. The announcement came through a striking poster that looks intense and powerful. Designed with a giant question mark as its centrepiece, the visual aesthetic features a burnt, gritty look, layered with old newspaper clippings that suggest a story carrying years of historical weight and noise. Adding to the intensity, the poster shows people holding red flags, hinting at themes of protest, anger, and a story that has been building up for a long time. View this post on Instagram A post shared by Sanjay Dutt (@duttsanjay) Sanjay Dutt’s face is positioned in the middle of the poster in profile, leaving the audience wondering if he holds the answers or is the one searching for them. Along with the visual is the intriguing tagline: "The question India never stopped asking." While specific plot details remain under wraps, the film's foundation goes back in history. Aakhri Sawal draws from the 100-year journey of the Rashtriya Swayamsevak Sangh (RSS), which was founded in 1925 by Keshav Baliram Hedgewar. The story focuses on a specific moment that the film suggests quietly shifted the course of the country and an episode not typically found in standard textbooks. The cast features an ensemble including Amit Sadh, Namashi Chakraborty, Sameera Reddy, Tridha Choudhury, and Neetu Chandra. Sharing the news on social media, Sanjay wrote, "The question India never stopped asking. Get ready to know the answer on 15th May only in cinemas." The announcement received a warm response, with his wife Maanayta Dutt posting fire emojis and fans expressing their excitement over this new project. Also Read: Dhurandhar: The Revenge Review: Marathon Actioner。
B |
C | 其中，药明康德来自美国客户收入为119.09亿元人民币，同比增长104%，占总营收67.07%。9月13日上午，药明康德方面回应称，目前，公司业务和运营一切正常。2022年上半年，康龙化成营业收入46.35亿元，同比上涨41.06%。
D | 随着国际化战略的推进，公司在英国和美国共有11个运营实体，超过1300名员工。2022年上半年，海外子公司营业收入占公司营业收入的12.14%。同期，博腾股份营收39.14亿元，同比上涨211.67%。2022年中报显示，公司于2017年收购的J-STAR，已在美国拥有2个研发厂地，能够承接临床早期原料药CRO及制剂服务。2022年上半年，J-STAR实现营业收入1.31亿元，同比增长22%。返回搜狐，查看更多责任编辑：
Current article:http://pk19.zhuankaizhuohangwangdixi.shop/25m1w/sgv76k.html
Published on:01:04:16